Business
Ifinatamab Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Extensive-Stage Small Cell Lung Cancer in IDeate-Lung01 Phase 2 Trial
BASKING RIDGE, N.J. & RAHWAY, N.J., September 07, 2025--Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). These data were presented today during a late-breaking presentation (OA06.03) and included as part of the press program at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of
About this update from Daiichi Sankyo Company, Limited
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":10600,"height":1888,"url":"https://media.zenfs.com/en/business-wire.com/8242f35223c327b1198c189710499263"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/ytDAS0FOBqes_C4_7v0HGA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTE3MTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/8242f35223c327b1198c189710499263","width":960,"height":171},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/ZNCfeVqPwnmFveexxIgxng--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD00Mjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/8242f35223c327b1198c189710499263","width":1200,"height":214}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"An objective response rate of 48.2% was observed with ifinatamab deruxtecan in these previously treated patients","length":112,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Discussions with global regulatory authorities underway","length":55,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":167,"olType":false},{"type":"text","content":"BASKING RIDGE, N.J. & RAHWAY, N.J., September 07, 2025--(BUSINESS WIRE)--Results from the IDeate-Lung01 phase 2 trial showed that ifinatamab deruxtecan (I-DXd) demonstrated clinically meaningful response rates in patients with previously treated extensive-stage small cell lung cancer (ES-SCLC). These data were presented today during a late-breaking presentation (OA06.03) and included as part of the press program at the 2025 World Conference on Lung Cancer hosted by the International Association for the Study of Lung Cancer (#WCLC25).","length":543,"tagName":"p"},{"type":"text","content":"Ifinatamab deruxtecan is a specifically engineered, potential first-in-class B7-H3 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed by Daiichi Sankyo and Merck (NYSE: MRK), known as MSD outside of the United States and Canada.","length":289,"tagName":"p"},{"type":"text","content":"SCLC is aggressive and progresses rapidly to the distant metastatic stage, which has a low five-year survival rate.1,2 While conventional standard of care treatments for patients with advanced SCLC may help improve outcomes, there is a need for additional subsequent ...